跳至主要内容
临床试验/NL-OMON49549
NL-OMON49549撤回不适用

*Differences in effect of treatment with mepolizumab and benralizumab on resident and inflammatory eosinophils. - DIMENSIO

niversitair Medisch Centrum Utrecht0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
入组人数
72

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Age * 18
  • * Diagnosis of severe refractory eosinophilic asthma
  • * Eligible for mepolizumab or benralizumab therapy according the national
  • recommendations for severe asthma of the Dutch society for lung diseases and
  • tuberculosis (NVALT guideline 2013): Patients with asthma, for whom alternative
  • diagnoses are excluded, comorbidity optimally treated, provoking factors
  • minimized and therapy compliance optimized, but despite this still have
  • insufficient asthma control (* 1.5 ACQ-7 or other questionnaire) or frequent
  • (*2 annually) severe exacerbations (systemic CS needed) while routinely using
  • high-dose asthma medication (* 1000 mcg/day fluticasone propionate equivalent
  • and/or daily OCS in combination with LABA or other controller medication); or
  • patients who can achieve asthma control only with systemic CS and are therefore
  • are risk for adverse effects or the corticosteroids.
  • * Treated with mepolizumab or benralizumab for at least 4 months.
  • * Before treatment with biologics a blood eosinophilia (* 150
  • eosinophils/microl blood) irrespective of steroid use

排除标准

  • * Any infection (eg. HIV, Hepatitis, STDs)
  • * Insulin dependent diabetes
  • * Smoking at present or in the last 12 months and/or a past history of more
  • than 10 pack years
  • * Proven allergic bronchopulmonary aspergillosis
  • * Auto-immune diseases
  • * Use of medication, excluding:
  • o Anticonceptives
  • o Pain killers, if used on average less than once a week
  • * exuberant alcohol consumption (for males > 36 glasses per week, for females
  • >24 glasses per week)
  • * Drug use
  • * History of cancer
  • * Use of biologicals other than mepolizumab or benralizumab
  • * daily oral steroid therapy during the three months preceding inclusion

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验